Lonza Group stock edges higher as investors digest recent CDMO updates

Published on 09/17/2026 at 14:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza Group stock traded around CHF 539.60 on September 17, 2026, leaving the shares roughly 10.8 percent below their 52-week high of CHF 597.80 from August 25, 2026. Analysts see average price targets near CHF 688.17, implying a substantial upside to the current level.

Lonza Group, CH0013841017, Illustration mit AI erstellt.

Lonza Group stock (ISIN CH0013841017) recently traded at around 539.60 CHF on the SIX Swiss Exchange as of September 17, 2026, putting the Swiss contract development and manufacturing organization clearly below its 52-week high but still comfortably above the yearly low.

Stock holds gains while staying below the 52-week high

According to finanzen.ch data from September 17, 2026, Lonza Group shares stood at 539.60 CHF at 12:28 local time, up 0.2 percent intraday after having opened the session at 541.00 CHF and reaching an intraday high of 545.40 CHF.

On the same day, the Swiss Market Index was quoted around 13,885 points, meaning Lonza Group stock was among the stronger names in the index in midday trading, even though the shares remained 10.79 percent below their 52-week high of 597.80 CHF set on August 25, 2026 and 18.70 percent above the 52-week low reported by the same overview.

Analyst expectations and valuation backdrop

A recent market snapshot from Zonebourse on September 17, 2026 cited a last closing price for Lonza Group of 538.40 CHF on the Swiss Exchange and an average analyst price target of 688.17 CHF, which corresponds to an upside of 27.82 percent compared with that closing level.

In the same context, finanzen.ch reported on September 17, 2026 that Lonza recently carried a stock market value of around 37.57 billion CHF, illustrating the company’s significant role within the Swiss Market Index and the broader European healthcare sector.

The same performance analysis showed that a hypothetical 100 CHF investment in Lonza shares one year earlier would now be worth 98.64 CHF based on the closing price of 538.40 CHF on September 16, 2026, implying a loss of 1.36 percent over the twelve-month period despite the stock trading materially above its 52-week low.

Earnings projections and CDMO positioning

For fundamentals, experts cited by finanzen.ch on September 17, 2026 estimate Lonza’s earnings for the year 2026 at 18.21 CHF per share, providing a current-year profit benchmark that investors use to gauge valuation against the prevailing share price around the mid-530 CHF range.

Beyond topline and earnings expectations, Lonza’s positioning in high-growth niches such as cell therapy and biomanufacturing continues to attract attention. A sector study published on September 17, 2026 by GlobeNewswire highlighted Lonza Group among prominent players in the global microcarriers market, underlining the company’s role in supplying technologies for cell therapy, vaccine production and broader biomanufacturing demand.

This backdrop matters for investors because it suggests that Lonza’s contract development and manufacturing operations stand to benefit from structurally rising demand for biologics and advanced therapies, even as near-term share price performance has been more subdued over the past twelve months compared with some peers in the sector.

Stock price level and investor takeaway

As of the latest completed session on September 16, 2026, Lonza Group stock closed at 538.40 CHF on the SIX Swiss Exchange, while intraday data on September 17, 2026 show the shares trading around 539.60 CHF, leaving the price roughly 10.8 percent below the 52-week high of 597.80 CHF and nearly 27.8 percent below the average analyst target of 688.17 CHF.